A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT

Bone Marrow Transplantation

Volumn 45, Issue 8, 2010, Pages 1325-1332

  Kanda, Y ^a   Yamashita, T ^b   Mori, T ^c   Ito, T ^d   Tajika, K ^e   Mori, S ^f   Sakura, T ^g   Hara, M ^h   Mitani, K ⁱ   Kurokawa, M ^j   Akashi, K ^k   Harada, M ^k,l  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^h EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

ⁱ DOKKYO MEDICAL UNIVERSITY   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

^l Omuta National Hospital   (Japan)

more..

Author keywords

antigenemia; CMV; preemptive therapy; real time PCR

Indexed keywords

CALCINEURIN; GANCICLOVIR; METHOTREXATE; METHYLPREDNISOLONE; VIRUS DNA;

ADULT; ANTIGENEMIA ASSAY; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FEMALE; GENE DOSAGE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SIDE EFFECT; VIRUS DETECTION; VIRUS REACTIVATION;

ADULT; ANTIGENS, VIRAL; BONE MARROW TRANSPLANTATION; COLITIS; CYTOMEGALOVIRUS INFECTIONS; DRUG DOSAGE CALCULATIONS; GANCICLOVIR; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREMEDICATION; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 77955570946     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.337     Document Type: Article

References (26)

1. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
2. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 1993; 118: 179-184.
3. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G, Bowden RA. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraft- ment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
4. Boeckh M, Ljungman P. How we treat CMV in hematopoietic cell transplant recipients. Blood 2009; 113: 5711-5719.
5. Ljungman P, Reusser P, de la Camara R, Einsele H, Engelhard D, Ribaud P et al. Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 2004; 33: 1075-1081.
6. Kanda Y, Mineishi S, Saito T, Seo S, Saito A, Suenaga K et al. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hemato- poietic stem cell transplantation: a single-center experience in Japan. Bone Marrow Transplant 2001; 27: 437-444. (Pubitemid 32201353)
7. Kanda Y, Mineishi S, Saito T, Saito A, Ohnishi M, Niiya H et al. Response-oriented preemptive therapy against cytome- galovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation 2002; 73: 568-572.
8. Einsele H, Ehninger G, Hebart H, Wittkowski KM, Schuler U, Jahn G et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
9. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture. Transplantation 1997; 64: 108-113.
10. Kanda Y, Chiba S, Suzuki T, Kami M, Yazaki Y, Hirai H. Time course analysis of semi-quantitative PCR and antigenae- mia assay for prevention of cytomegalovirus disease after bone marrow transplantation. Br J Haematol 1998; 100: 222-225.
11. Mori T, Okamoto S, Watanabe R, Yajima T, Iwao Y, Yamazaki R et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 777-782.
12. Gerna G, Lilleri D, Caldera D, Furione M, Zenone Bragotti L, Alessandrino EP. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008; 41: 873-879.
13. Lilleri D, Gerna G, Furione M, Bernardo ME, Giorgiani G, Telli S et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood 2007; 110: 2757-2760.
14. Verkruyse LA, Storch GA, Devine SM, Dipersio JF, Vij R. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load or = 10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant 2006; 37: 51-56.
15. Nakai K, Kanda Y, Mineishi S, Saito T, Ohnishi M, Niiya H et al. Suspected delayed immune recovery against cytomega- lovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. Bone Marrow Transplant 2002; 29: 237-241.
16. Kanda Y, Mineishi S, Nakai K, Saito T, Tanosaki R, Takaue Y. Frequent detection of rising cytomegalovirus antigenemia after allogeneic stem cell transplantation following a regimen containing antithymocyte globulin. Blood 2001; 97: 3676-3677.
17. Kurihara T, Hayashi J, Ito A, Asai T. CMV antigenemia assay using indirect ALP-immunostaining in bone marrow transplant recipients. Transplant Proc 1996; 28: 1750-1753.
18. Tanaka Y, Kanda Y, Kami M, Mori S, Hamaki T, Kusumi E et al. Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30: 315-319.
19. Asano-Mori Y, Kanda Y, Oshima K, Watanabe T, Shoda E, Motokura T et al. Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. J Antimicrob Chemother 2006; 57: 1004-1007.
20. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H et al. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol 2008; 87: 310-318.
21. Mori T, Mori S, Kanda Y, Yakushiji K, Mineishi S, Takaue Y et al. Clinical significance of cytomegalovirus (CMV) anti- genemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33: 431-434.
22. Boeckh M, Woogerd PM, Stevens-Ayers T, Ray CG, Bowden RA. Factors influencing detection of quantitative cytomegalovirus antigenemia. J Clin Microbiol 1994; 32: 832-834.
23. Gerna G, Revello MG, Percivalle E, Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992; 30: 1232-1237.
24. Grundy JE, Ehrnst A, Einsele H, Emery VC, Hebart H, Prentice HG et al. A three-center European external quality control study of PCR for detection of cytomegalovirus DNA in blood. J Clin Microbiol 1996; 34: 1166-1170.
25. Gerna G, Percivalle E, Torsellini M, Revello MG. Standardization of the human cytomegalovirus antigenemia assay by means of in vitro-generated pp65-positive peripheral blood polymorphonuclear leukocytes. J Clin Microbiol 1998; 36: 3585-3589.
26. Verschuuren EA, Harmsen MC, Limburg PC, van Der Bij W, van Den Berg AP, Kas-Deelen AM et al. Towards standardization of the human cytomegalovirus antigenemia assay. Intervirology 1999; 42: 382-389.